Extracorporeal SW Therapy for PAD lation of vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS). 9-14 Because of its noninvasive nature, our low-energy SW therapy is applicable for both patients with complicating disorders and elderly patients, and can be repeated if needed.
In the present study, we thus examined whether our lowenergy SW therapy also improves the walking ability of PAD patients with intermittent claudication.
Methods

Patients
We enrolled PAD patients who were classified as Fontaine II. In the first trial (a pilot study), we treated 6 patients from September 2007 to July 2008. After modifying the treatment protocol based on the results of the pilot study, we then treated another 12 patients in the second trial from September 2008 to May 2011. Exclusion criteria were as follows: absence of PAD (ankle-brachial pressure index [ABI] >0.90 at rest), asymptomatic PAD, unstable coronary artery disease, current smoking, inability to perform treadmill test, active cancer, and dementia. Smoking history was obtained from the patient's self-report and non-smoking for more than 6 months was required to participate in the present study. Antiplatelet agents were administered for at least 1 year before enrolment and all antiplatelet agents were continued during the follow-up period. Both trials were approved by the ethical committees of Tohoku University, and written informed consent was given by each patient.
Low-Energy SW Therapy
Low-energy SW therapy was performed with a SW generator (Modulith ® SLC, Storz Medical AG, Switzerland) (Figure 1) . Based on our previous work, 1 SW session consisted of 200 shots in each of 40 sites on the ischemic calf muscle at 0.1 mJ/mm 2 , approximately 10% of the energy level that is used for lithotripsy. 9-17 If the patient felt discomfort in the legs during the SW therapy, the energy level was reduced to a tolerable level and then the energy level was gradually increased.
First Trial (Pilot Study)
We treated 6 limbs in 6 patients (5 males/1 female, 67-82 years old; all patients had arteriosclerosis obliterans) with the lowenergy SW therapy 3 times/week in the first (days 1, 3, 5) and fifth weeks (days 29, 31, 33) (Figure 2 ).
Second Trial
Based on the results of the pilot study, we modified the treatment protocol. In the second trial, the low-energy SW therapy was performed 3 times/week for 3 consecutive weeks (Figure 2) . We treated 19 limbs in another 12 PAD patients (10 males/2 females, 60-86 years old), comprising arteriosclerosis obliterans in 10, Buerger's disease in 1 and polyarteritis nodosa in 1 (Table) .
Evaluation of Walking Ability
Walking Impairment Questionnaire (WIQ) Subjective walking ability was evaluated in the second trial with a WIQ (Japanese version). 18 The patients answered the WIQ before and 4, 8, 12 and 24 weeks after the SW therapy.
ABI ABI was examined before and 4, 8, and 12 weeks after the SW therapy in the first trial, and before and 4, 8, 12, and 24 weeks after the SW therapy in the second trial. All measurements were performed with an ABI measurement device (VaSera VS-1500A ® ; Fukuda Denshi, Tokyo, Japan) at rest.
Maximum Walking Distance
The treadmill test was performed under the condition of 2.4 km/h, 12% degrees in incline with treadmill device, and the maximum walking distance was measured (up to 400 m in 10 min). The maximum walking distance was evaluated before and 4, 8, and 12 weeks after the SW therapy in the first trial, and before and 4, 8, 12, and 24 weeks after the SW therapy in the second trial. Seven patients enrolled in the second trial had bilateral lesions and their maximum walking distance was measured in the more severely diseased leg.
Recovery The near-infrared spectroscopy probes were attached to the calf muscle, and the recovery time of TOI, which reflects local O2 supply, was obtained. CT Angiography CT angiography was performed to evaluate collateral vascular growth before and 12 weeks after the SW therapy in the first trial, and before and 24 weeks after the SW therapy in the second trial. The angiographic images were independently evaluated by 2 radiologists in a blinded manner.
Statistical Analysis
Statistical analyses were performed by unpaired t-test using StatMate 4. The results are expressed as means ± standard deviations (SD). Differences were considered statistically significant at P<0.05.
Results
First Trial (Pilot Study)
There were no significant changes in ABI during the follow-up period in the first trial (data not shown). After the SW therapy, the maximum walking distance was significantly increased at 4 weeks (130±27% from baseline, P<0.05) and 8 weeks PAD, peripheral artery disease; Buerger, Buerger's disease; PN, polyarteritis nodosa; I, iliac region (from aortic bifurcation to external iliac artery); F, femoral region (common/superficial/deep femoral artery); IP, infra-popliteal region. Extracorporeal SW Therapy for PAD (162±30% from baseline, P<0.05). However, the increased maximum walking distance was not sustained at 12 weeks in 3 of the 6 patients (146±63% from baseline, P=0.14). Thus, we modified the treatment protocol following our previous study of hindlimb ischemia in a rabbit model. 11 No detectable change in collateral vessels was observed with CT angiography at 12 weeks after the SW therapy.
Second Trial WIQ The pain and distance subscale scores were significantly increased at 8, 12 and 24 weeks (Figure 4) . The stairs subscale score was increased only at 8 weeks and no significant change was observed in the speed subscale score (Figure 4) . ABI There were no significant changes in ABI during the follow-up period (baseline: 0.57±0.15, 4 weeks: 0.58±0.13, 8 weeks: 0.58±0.13, 12 weeks: 0.57±0.14, 24 weeks: 0.59±0.12, all P=NS).
Maximum Walking Distance After the SW therapy, the maximum walking distance was significantly increased at 4 weeks (151±37% from baseline, P<0.01), and was maintained at 8 weeks (161±56%, P<0.01), 12 weeks (171±75%, P<0.01) and 24 weeks (180±74%, P<0.01) (Figure 5) . One patient failed to undergo the treadmill test at 4 weeks because of knee joint pain, and another patient at 24 weeks because of a respiratory disorder.
Recovery Time of TOI The recovery time of TOI was significantly shortened at 4, 8, 12 and 24 weeks compared with baseline (all P<0.01) (Figure 6) .
CT Angiography No increase in visible collateral vessels was noted on the CT angiograms at 24 weeks after the SW therapy.
Discussion
In the present study, the low-energy SW therapy significantly improved symptoms, walking ability and peripheral perfusion without any adverse effects in PAD patients with intermittent claudication. To our knowledge, this is the first report to demonstrate the beneficial effects of low-energy SW therapy for PAD patients.
Treatment Protocol
In the first trial, although the maximum walking distance was increased at 4 weeks after the SW therapy, the beneficial effect was not sustained for a longer period. Thus, we modified the protocol by increasing the duration of the SW therapy in the second protocol, and we were able to confirm sustained beneficial effects of the therapy on the walking ability of PAD patients. In our previous studies, 1-week treatment (total 3 times) was enough for the treatment of myocardial ischemia in pigs and humans, 9,10,12-16 whereas the 3-week treatment (total 9 times) was required for the treatment of hindlimb ischemia The pain subscale and the distance subscale scores were significantly increased and were maintained for 24 weeks after the shock wave therapy. Extracorporeal SW Therapy for PAD in rabbits. 11 Although the mechanisms for the different optimal SW conditions between the heart and the legs remain unclear, it is conceivable that therapeutic angiogenesis may be more effectively induced in the heart than in the legs. Further studies are needed to address this point.
Effects of Low-Energy SW Therapy on Symptoms
In the second trial, the low-energy SW therapy significantly improved the pain and distance subscale scores of the WIQ, probably because of improved peripheral perfusion and local O2 supply as evidenced by the improved recovery time of TOI. In contrast, the SW therapy did not sufficiently improve the speed or stairs subscale scores. Most PAD patients with intermittent claudication walk slowly and subconsciously avoid the use of stairs in their daily life, which could be one of the reasons why the SW therapy did not improve the speed and stairs subscale scores. Although cilostazol has also been reported to improve the WIQ scores, 19 the beneficial effect of the SW therapy on the WIQ scores in the present study is superior to that of cilostazol.
Effects of the SW Therapy on Walking Ability
In the second trial, the SW therapy significantly improved the walking ability of PAD patients with intermittent claudication. This beneficial effect was associated with a significant reduction in the recovery time of TOI, reflecting improved calf Figure 5 . Maximum walking distance during the treadmill test in the second trial was significantly increased and was maintained for 24 weeks after the shock wave therapy. Figure 6 . Recovery time of tissue oxygenation index in the second trial was significantly shortened and the improvement was maintained for 24 weeks after the shock wave therapy. SERIZAWA F et al.
muscle blood flow and oxygenation. These results indicate that the SW therapy ameliorates the walking disability by improving peripheral perfusion in ischemic limbs.
Recently, Norgren et al demonstrated that sarpogrelate ameliorated the walking disability and increased the maximum walking distance at 24 weeks by 40% in patients classified as Fontaine II. 20 Regensteiner et al 19 and Pande et al 21 also demonstrated that cilostazol prolonged the maximum walking distance at 24 weeks by 50-76%. Exercise rehabilitation has also been reported to improve walking capacity by 25-65%. 22- 24 The present study demonstrates that the SW therapy improves walking ability to the same extent as cilostazol without any adverse effects.
Mechanism of the Low-Energy SW Therapy
We have previously reported that low-energy SW therapy ameliorates myocardial ischemia in patients with severe angina pectoris 10, 13 and increases capillary density in ischemic myocardium and ischemic limbs in animal models. 9,11,15,16 There are also several animal studies and case reports in humans showing that SW therapy accelerates wound healing in skin graft and chronic ulcers. 25- 28 We and others have demonstrated in cultured human umbilical vein endothelial cells that low-energy SW therapy enhances NO production and expression of VEGF and its receptor, fms-related tyrosine kinase 1 (Flt-1), in vitro 9, 29 and that the upregulation of VEGF and eNOS was involved in the SW-induced angiogenesis in vivo. 9, 16 In addition, it was reported that low-energy SW applied to bone-marrow-derived mononuclear cells enhances VEGF production from the cells and their differentiation into endothelial phenotype cells 30 and that low-energy SW activates proliferation and differentiation in cardiac primitive cells. 31 Low-energy SW therapy was also reported to increase the expression of stromal-derived factor 1 in ischemic tissue, leading to enhanced recruitment of progenitor cells in a rat model of hindlimb ischemia. 32 Taken together, these data suggest that the beneficial effects of lowenergy SW therapy on the walking ability of PAD patients are attributed, at least in part, to enhancement of several intrinsic angiogenic pathways.
Study Limitations
Several limitations of the present study should be mentioned. First, this was not a randomized controlled study and there was a small number of patients. We created the present protocol because patients can easily feel the SW-induced compression sensation (but not pain) when SW is applied to the calf muscle. Furthermore, we found a statistically significant beneficial effect of the SW therapy in the present patients (80% increase in the walking distance at 24 weeks) and the effect was greater than in a previous study in which some placebo effects were noted (35% increase at 6 months in a phase III clinical trial of oral beraprost sodium in PAD patients with intermittent claudication). 33 Thus, we consider that our SW therapy is superior to the placebo effect. However, this point needs to be confirmed in future studies with a large number of patients. Second, SW therapy failed to significantly improve the ABI and no increase in visible collateral vessels was noted by CT angiography although the SW therapy improved not only symptoms and walking ability but also local O2 supply. Although the effect of the SW therapy appears to be mediated primarily by angiogenesis, the ABI and CT may not be sensitive enough to detect the angiogenesis in the ischemic calf muscle. A similar phenomenon was often observed in excercise rehabilitation studies of PAD patients and a recent metaanalysis reported that exercise rehabilitation could ameliorate the walking disability but did not improve ABI. 23 In PAD patients' calf muscles, increased muscle cell apoptosis and decreased capillary density are noted at the cellular and tissue levels, and muscle energetics are associated with mitochondrial dysfunction. 34, 35 Bauer et al reported that mitochondrial dysfunction may affect the muscle oxygen utilization rate and accelerate endothelial cell damage. 36, 37 We consider that our SW therapy may contribute, at least in part, to an improvement in mitochondrial dysfunction and muscle oxygen utilization. Although muscle biopsy may be useful to examine the histological changes, biopsy of the calf muscle of PAD patients is not usually recommended because of its invasive nature. Third, although supervised exercise training has been reported to improve walking ability by 25-65% in PAD patients, 22-24 it was not performed in the present study because the patients did not have an access to daily supervised exercise training. The possible effects of low-energy SW therapy combined with conventional therapeutic strategies, such as supervised exercise training, bypass surgery and endovascular intervention, remain to be examined. Fourth, the maximum walking distance at 24 weeks was increased in all patients. However, in only 1 patient wasthe maximum walking distance increased by less than 35% at 24 weeks. This patient had a single lesion caused by an occluded external iliac stent and the vascular tree below the femoral artery was intact. Considering potential mechanisms such as angiogenesis, SW therapy applied to the ischemic calf muscle may be more effective in patients with infrapopliteal lesions. Finally, in the present study, only PAD patients in Fontaine stage II were enrolled. In order to examine whether low-energy SW therapy is also effective in PAD patients with critical limb ischemia, we are now conducting a third clinical trial with PAD patients in Fontaine stages III and IV.
Conclusions
The present study demonstrates for the first time that our noninvasive low-energy SW therapy ameliorates the walking disability of PAD patients without any adverse effects. Further studies are needed to elucidate the detailed mechanisms of the beneficial effects of SW therapy.
